• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2023

View Archived Issues
Colorized scanning electron micrograph of MRSA.

For fighting staph infections, multitasking fusion protein is perfect 10

Researchers at NYU Langone Health and Janssen Biotech Inc. have reported on mAbtyrins, bioengineered molecules composed of human monoclonal antibodies and centyrins that are a new way to fight Staphylococcus aureus infection on all fronts.In their experiments, which were published in Cell Host & Microbe on April 24, 2023, the team described mAbtyrin, as “a protein-based therapeutic that targets 10 disease-causing mechanisms employed by S. aureus,” senior author Victor Torres told BioWorld. Read More

Unique binding pocket is clue to develop inhibitors against Helicobacter pylori

A unique characteristic of Helicobacter pylori could serve to end infections of this gastric bacterium. A group of scientists from the University of Munich have found that this pathogen has a strategic point in its mitochondrial respiratory complex I that could be targeted with inhibitors. “We did not look for respiration inhibitors in the first place,” co-senior author Wolfgang Fischer told BioWorld. “We screened libraries with a reporter assay, looking for something different, a particular protein secretion, the secretion system type (T4SS). Then, we found that a lot of compounds inhibit this process. From these compounds, we came to the point that they are actually respiration inhibitors,” he explained. Read More
Dorsal striatum and its neurons in Huntington's disease

Life Edit Therapeutics presents preclinical data on Huntington’s disease program

Life Edit Therapeutics Inc., an Elevatebio LLC company, has presented the first preclinical data from the its Huntington’s disease program. Read More
Illustration of intestines with inflammation

Pan-Biome compound shows protective effects in mouse model of colitis

Pan-Biome Pharmaceuticals Inc.’s lead compound has shown protective effects in a preclinical model of inflammatory colitis. Read More

Wisconsin Alumni Research Foundation patents turbinmicin analogues for fungal infections

Turbinmicin analogues reported to be useful for the treatment of fungal infections have been described in a recent Wisconsin Alumni Research Foundation (WARF) patent. Read More
Drug R&D concept image.

Insilico Medicine reports the discovery of potent anticancer compounds

Researchers from Insilico Medicine Inc. presented preclinical data for several newly discovered anticancer small-molecule candidates. Read More

Blacksmith Medicines divulges LpxC inhibitor prodrugs for treatment of UTIs

A Blacksmith Medicines Inc. patent describes the development of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of complicated urinary tract infections (UTIs). Read More
Eya and DNA illustration

Stoke Therapeutics’ ASO STK-002 cleared to enter clinic in U.K. for autosomal dominant optic atrophy

Stoke Therapeutics Inc. has received clinical trial application (CTA) clearance from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study (OSPREY) of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA). Read More

Boehringer Ingelheim patents new PROTACs for treatment of cancer

Research at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the development of proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker. Read More

SOS1 inhibitors described in Shanghai Allist Pharmaceuticals patent

Son of sevenless homolog 1 (SOS1) inhibitors have been detailed in a Shanghai Allist Pharmaceuticals Co. Ltd. patent and described as useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome (neurofibromatosis type 1-like syndrome), neurofibromatosis type 1, Noonan syndrome and Splenomegaly, among others. Read More
Photomicrograph of core biopsy of prostate gland showing histology of adenocarcinoma in patient with elevated PSA.

ARV-766, an oral AR degrading PROTAC that targets wild-type and clinically relevant AR mutants

Researchers from Arvinas Inc. and affiliated organizations presented the discovery and preclinical evaluation of ARV-766, a novel androgen receptor (AR) degrading proteolysis targeting chimera (PROTAC), being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Read More

Bispecific antibody ASP-2138 demonstrates antitumor efficacy in CLDN18.2-expressing tumors

Claudin 18.2 (CLDN18.2) is involved in the formation of tight junctions and is expressed in normal gastric mucosa, maintaining its expression during malignant transformation of the gastric epithelium. It is also aberrantly expressed in other tumor types, such as esophageal, pancreatic and lung adenocarcinoma, making it an attractive target for cancer immunotherapy. Read More

Viva Star Biosciences patent reveals NLRP3 inflammasome inhibitors

Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease. Read More
Antibodies

Albatroz Therapeutics secures funding to develop therapeutic antibodies to treat solid tumors and arthritis

Albatroz Therapeutics Pte Ltd. has secured $3 million in funding to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis. Read More

CDH6-targeting ADC CUSP-06 shows antitumor efficacy in preclinical cancer models

Cadherin 6 (CDH6) is a transmembrane protein with high expression during embryonic kidney development, with very limited expression in adult tissues but overexpressed in several malignancies such as ovarian or renal cancer, and it is tied disease progression and poor prognosis. This pattern of expression makes it an attractive target for antibody-drug conjugate (ADC) development. Read More

Other news to note for April 26, 2023

Additional early-stage research and drug discovery news in brief, from: Dyve Biosciences, Eyevensys, Palatin Technologies, Sernova, Valitor, Zyversa Therapeutics. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe